Project Grant R21AG085108

Award Date 4/15/24
Completion Date 3/31/26
Dollars Obligated $461K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $427,625.00 to The Washington University in St. Louis to develop a novel in vitro model for studying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research project will employ direct neuronal conversion to generate induced motor neurons and cortical...
This $1,157,896 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at Brown University focused on elucidating the mechanistic basis of transketolase-mediated suppression of neurodegeneration in amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD). The grantee will study multiple models of ALS/FTD using Drosophila genetics and analyze molecular readouts such as redox state, autophagy,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $697,907 to Thomas Jefferson University to investigate the role of the C-JUN/transposable element (TE)/cGAS/STING pathway in the pathogenesis of C9ORF72-associated amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). The key products and services...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $120,504 to Carnegie Mellon University to develop peptide nucleic acid (PNA) oligomers for targeted disruption of biomolecular condensates in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The key objectives are to: (a) fluorescently label RNAs suspected of participating in biomolecular condensates, and (b) disrupt...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
The National Institute on Aging (NIA) awarded a $630,496 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The 5-year grant, awarded on June 1, 2025, supports research to investigate the underlying mechanisms of proteostasis dysfunction and neuroinflammation in frontotemporal dementia (FTD) caused by granulin (GRN) deficiency. The research aims to better define alterations in...
This $224,140 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to elucidate the mechanisms of circuit dysfunction in frontotemporal dementia (FTD) caused by the C9ORF72 gene mutation. The research aims to monitor the progression of neuronal activity and its relationship to neuronal loss, as well as determine whether neuronal hyperactivity can drive the progression of FTD pathology and behavioral deficits. The award recipient, The General...
This $432,802 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research focused on identifying gene expression changes associated with the C9ORF72 mutation in frontotemporal dementia (FTD). The primary awardee, Pennsylvania State University (doing business as Penn State Milton S. Hershey Medical Center), will cross-validate...
This federal Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to improve understanding of frontotemporal lobar degeneration (FTLD), a group of neurodegenerative disorders. The total award amount is $1,076,760.00 and the performance period runs from September 30, 2024 to August 31, 2029. The key objectives of this grant are to: 1) Generate a humanized FTLD-TDP mouse model by transplanting patient-derived microglia into mice...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting the development and optimization of a new animal model for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The $374,349 award to the University of North Carolina at Chapel Hill aims to demonstrate the progressive ALS/FTD-like phenotype in aged cohorts of...

MECHANISTIC INVESTIGATION OF INNATE IMMUNITY IN A DROSOPHILA MODEL OF FRONTOTEMPORAL DEMENTIA - FRONTOTEMPORAL DEMENTIA (FTD) IS THE SECOND MOST COMMON PRESENILE DEMENTIA AFTER ALZHEIMER'S DISEASE AND SHARES MANY PATHOLOGICAL AND GENETIC OVERLAPS WITH ALS. THE MOST COMMON GENETIC CAUSE OF FTD AND ALS IS A GGGGCC HEXANUCLEOTIDE REPEAT EXPANSION IN THE FIRST INTRON OF THE C9ORF72 GENE. ALTHOUGH RNA TOXICITY AND C9ORF72 HAPLOINSUFFICIENCY MAY ALSO CONTRIBUTE TO DISEASE PATHOGENESIS IN C9ORF72-RELATED FTD/ALS, MUCH EFFORTS HAS FOCUSED ON INVESTIGATING THE TOXICITY OF DIPEPTIDE REPEAT (DPR) PROTEINS THAT CAN BE TRANSLATED FROM BOTH SENSE AND ANTISENSE REPEAT RNAS. HOW THESE DPR PROTEINS, ESPECIALLY POLY(GR), CAUSE NEURODEGENERATION AT THE MOLECULAR MECHANISTIC LEVEL REMAINS LARGELY UNKNOWN. IN THIS EXPLORATORY R21 GRANT APPLICATION, BASED ON OUR RECENT FINDINGS THAT SEVERAL ANTIMICROBIAL PEPTIDE GENES, SUCH AS METCHNIKOWIN (MTK), ARE UPREGULATED WITH POLY(GR) TOXICITY IN DROSOPHILA AND THAT MTK KNOCKDOWN IN THE EYE OR IN ALL NEURONS SUPPRESSES POLY(GR) NEUROTOXICITY, WE PROPOSE TO FURTHER INVESTIGATE THIS UNDERSTUDIED PATHWAY IN NEURODEGENERATION. IN PARTICULAR, WE WILL INVESTIGATE THE MOLECULAR MECHANISMS UNDERLYING THE EFFECTS OF MTK ON POLY(GR) TOXICITY, EXPLORE THE NON-CELL AUTONOMOUS NEURODEGENERATIVE ACTIVITY OF MTK, AND FINALLY ATTEMPT TO IDENTIFY MAMMALIAN AMP(S) THAT MAY FUNCTION IN A SIMILAR FASHION AS DROSOPHILA MTK IN THE MOLECULAR PATHOGENESIS OF FTD/ALS. THESE STUDIERS WILL SHED NEW LIGHT ON PATHOGENIC MECHANISMS OF FTD/ALS AND MAY HELP IDENTIFY NOVEL THERAPEUTIC TARGETS FOR THESE DISORDERS.

Posted 4/3/24, 12:00 AM